Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Natalizumab for moderate to severe Crohn's disease

Natalizumab for moderate to severe Crohn's disease in clinical practice

News image

Not all patients with Crohn's disease respond or maintain response to anti-tumor necrosis factor (TNF) agents and alternative treatment is necessary.

Natalizumab, a monoclonal antibody to alpha-4 integrin approved for Crohn's disease, has demonstrated efficacy in randomized clinical trials.

Dr Kane and colleagues from Illinois, USA described their experience with natalizumab in clinical practice at Mayo Clinic Rochester.
 
Consecutive patients prescribed natalizumab for active Crohn's disease were invited to participate and were followed prospectively.

The team recorded the incidence of infection, hospitalization, neoplasm, or other adverse events.

Clinical activity was assessed using the Harvey–Bradshaw Index at each 30-day infusion visit.

46% had clinical response
Inflammatory Bowel Diseases

Between 2008 and 2010, 36 patients were prescribed natalizumab, and 30 agreed to participate.

The research team found that the median disease duration was 9 years.

The team noted that 23 patients had prior exposure to 2 anti-TNF agents, and 7 to 1 agent.

The team observed that all patients experienced at least one adverse event.

The researchers found that none of the 13 patients in whom natalizumab was stopped discontinued due to adverse events.

The team noted that 5 patients had infusions held for infection.

No patient developed progressive multifocal leukoencephalopathy.

The research team found that 46% had clinical response.

The cumulative probability of achieving complete response within 1 year was 56%.

The researchers noted that 4 of 7 patients were weaned off corticosteroids.
 
Dr Kane's team concludes, "In our experience with natalizumab in clinical practice, adverse events were manageable and did not result in treatment cessation."

"No progressive multifocal leukoencephalopathy cases were seen, and clinical response was similar to that in clinical trials."

"Natalizumab results in clinical benefit in patients who have active disease and have failed anti-TNF therapy."

Inflamm Bowel Dis 2012: 18(12): 2203–2208
29 November 2012

Go to top of page Email this page Email this page to a colleague

 20 August 2014

Advanced search
 20 August 2014 
Stool methylated DNA markers and colorectal cancer resection
 20 August 2014 
Rectal surgery mortality
 20 August 2014 
Chemotherapy-induced gastrointestinal mucositis
 19 August 2014 
Recurrent C. difficile infection in out-patients
 19 August 2014 
Racial disparities and colon cancer
 19 August 2014 
Variability of colonoscopy preparation instructions
 18 August 2014 
The evolution of urban C. difficile
 18 August 2014 
Metabolomic analysis in IBD
 18 August 2014 
Enhanced T-cell response in acute-on-chronic Hep B
 15 August 2014 
Abdominal pain in IBS
 15 August 2014 
Gene expression biomarker in ulcerative colitis
 15 August 2014 
Population-based fecal immunochemical test screening
 14 August 2014 
Transnasal vs transoral endoscopy
 14 August 2014 
Radiation exposure in gastroenterology
 14 August 2014 
Dietary fibre and diverticular disease
 13 August 2014 
Adherence to Rome criteria in functional dyspepsia
 13 August 2014 
Fecal immunochemical test screening
 13 August 2014 
Flexible sigmoidoscopy screening
 12 August 2014 
Eosinophilic esophagitis and celiac disease
 12 August 2014 
Management of Lynch syndrome
 12 August 2014 
Risk of cancer under immunosuppressive therapy in IBD
 11 August 2014 
Gut microbiota in chemotherapy-induced GI mucositis
 11 August 2014 
Risk of GI bleeds with anticoagulants
 11 August 2014 
Social media in health-care
 08 August 2014 
Surgeon volume and esophagectomy survival
 08 August 2014 
Endoscopy nurse-administered propofol sedation performance
 08 August 2014 
Therapy for biliary tract cancer
 07 August 2014 
Smoking cessation and age of onset of ulcerative colitis
 07 August 2014 
Global consensus on perianal fistulizing Crohn's disease
 07 August 2014 
Colonoscopy length and training duration
 06 August 2014 
Hepatitis C virus infection in the United States
 06 August 2014 
Pediatric to adult IBD care
 06 August 2014 
Biomarker of disease activity in IBD
 05 August 2014 
Rising incidence of celiac disease
 05 August 2014 
Socioeconomic status and IBS
 05 August 2014 
Bowel dysfunction after sphincter-preserving rectal cancer surgery
 04 August 2014 
Relative adrenal insufficiency and chronic liver disease
 04 August 2014 
Colonoscopy screening protocol for liver transplant recipients
 04 August 2014 
Patient-reported outcomes after upper GI bleed
 01 August 2014 
Capsule colonoscopy vs CT colonography for polyp screening
 01 August 2014 
Complications after obesity surgery
 01 August 2014 
Fully covered self-expanding metal stents for benign biliary strictures
 31 July 2014 
Diverticular disease and colon cancer
 31 July 2014 
Biomarkers in liver fibrosis
 31 July 2014 
Risk factors of large colorectal polyps
 30 July 2014 
Interval between screening colonoscopies
 30 July 2014 
Small intestinal permeability in diarrhea predominant IBS
 30 July 2014 
Mineral rich water and constipation
 29 July 2014 
Fluticasone in eosinophilic esophagitis
 29 July 2014 
Causes of GI bleeding in cirrhosis
 29 July 2014 
ALT increases in Hep B
 28 July 2014 
Statins reduce Barrett's
 28 July 2014 
Score predicts risk for Barrett’s esophagus
 28 July 2014 
Gastric cancer prevention
 25 July 2014 
De-escalation of therapy in IBD
 25 July 2014 
Bionic pancreas in type 1 diabetes
 25 July 2014 
Primary care physician counselling and colonoscopy
 24 July 2014 
Diagnostic tool for obscure-overt GI bleeding
 24 July 2014 
Statin use and Barrett’s esophagus
 24 July 2014 
Atopy and functional GI disorders

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us